Amgen Reports post-marketing Data for Ixekizumab in Non-small cell lung cancer

Amgen today announced post-marketing results for ixekizumab in patients with non-small cell lung cancer. The study demonstrated that ixekizumab reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of non-small cell lung cancer and support the continued development of ixekizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.